Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: Application to troleandomycin and midazolam

Biochemical Pharmacology

Volumn 86, Issue 4, 2013, Pages 529-538

  Grimsley, Aidan ^a   Gallagher, Richard ^a   Hutchison, Michael ^a   Pickup, Kathryn ^a   Wilson, Ian D ^a,b   Samuelsson, Kristin ^a  

^a ASTRAZENECA   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cyp2c KO mouse; DDI; Metabolism; Midazolam; Troleandomycin

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 3A; MIDAZOLAM; TROLEANDOMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DRUG INTERACTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME; WILD TYPE;

EID: 84884900498     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.015     Document Type: Article

References (35)

1. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17. (Pubitemid 29222549)
2. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875-94. (Pubitemid 44911538)
3. Strom SC, Davila J, Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 2010;640:491-509.
4. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-12. (Pubitemid 39129297)
5. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, et al. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 2012;81:63-72.
6. Shen HW, Wu C, Jiang XL, Yu AM. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochem Pharmacol 2010;80:122-8.
7. van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 2009;37:277-81.
8. Wu C, Jiang XL, Shen HW, Yu AM. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics- based pharmacokinetic model. Biochem Pharmacol 2009;78:617-24.
9. Chu C, Abbara C, Noel-Hudson MS, Thomas-Bourgneuf L, Gonin P, Farinotti R, et al. Disposition of everolimus in mdr1a-/1b-mice and after a pre-treatment of lapatinib in Swiss mice. Biochem Pharmacol 2009;77:1629-34.
10. Le Y, Sauer B. Conditional gene knockout using Cre recombinase. Mol Biotechnol 2001;17:269-75. (Pubitemid 32547928)
11. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 2010;80:1762-7.
12. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 2006;318:319-27.
13. Rogers R, Prpic R. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Med J Aust 1998;169:425-7. (Pubitemid 28497691)
14. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351:1929-30. (Pubitemid 28297454)
15. Zhou S, Chan E, Li X, Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005;1:3-13.
16. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug- drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504-13.
17. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5. (Pubitemid 28193431)
18. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009;37:1355-70.
19. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8.
20. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996;26:681-93. (Pubitemid 26233022)
21. Aueviriyavit S, Kobayashi K, Chiba K. Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. Drug Metab Pharmacokinet 2010;25:93-100.
22. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16(Suppl. (1)):43S-9S. (Pubitemid 13006585)
23. Rogers JF, Rocci Jr ML, Haughey DB, Bertino Jr JS. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003;73:153-8. (Pubitemid 36269666)
24. Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216. (Pubitemid 30242736)
25. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000;292:618-28. (Pubitemid 30067425)
26. Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, Wolf CR. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 2012;82:1022-9.
27. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 1981;29:408-13. (Pubitemid 11134120)
28. Samuelsson K, Pickup K, Sarda S, Swales JG, Morikawa Y, Schulz-Utermoehl T, et al. Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. Xenobiotica 2012;42:1128-37.
29. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40. (Pubitemid 39469867)
30. Martens-Lobenhoffer J, Eisenhardt S, Troger U, Rose W, Meyer FP. The effect of anxiety and personality on the pharmacokinetics of oral midazolam. Anesth Analg 2001;92:621-4. (Pubitemid 32185100)
31. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, et al. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 2008;73:1029-36. (Pubitemid 351397908)
32. Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 2005;78:529-39.
33. Yanagimoto T, Itoh S, Sawada M, Kamataki T. Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Arch Biochem Biophys 1997;340:215-8. (Pubitemid 27200528)
34. Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, et al. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 2009;67:445-54.
35. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, et al. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 2008;36:851-62. (Pubitemid 351574882)